NCCN task force report: bone health in cancer care
JR Gralow, JS Biermann, A Farooki, MN Fornier… - Journal of the National …, 2013 - jnccn.org
Bone health and maintenance of bone integrity are important components of comprehensive
cancer care. Many patients with cancer are at risk for therapy-induced bone loss, with …
cancer care. Many patients with cancer are at risk for therapy-induced bone loss, with …
[HTML][HTML] Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational …
L Karlsson, J Lundkvist, E Psachoulia, M Intorcia… - Osteoporosis …, 2015 - Springer
The objectives of this study were to estimate persistence with denosumab and put these
results in context by conducting a review of persistence with oral bisphosphonates …
results in context by conducting a review of persistence with oral bisphosphonates …
[HTML][HTML] Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States
E Durden, L Pinto, L Lopez-Gonzalez, P Juneau… - Archives of …, 2017 - Springer
This retrospective, observational study assessed 2-year persistence and compliance by
treatment, route of administration, and dosing frequency in postmenopausal women …
treatment, route of administration, and dosing frequency in postmenopausal women …
[HTML][HTML] Hyperkalemia in real-world patients under continuous medical care in Japan
N Kashihara, S Kohsaka, E Kanda, S Okami… - Kidney international …, 2019 - Elsevier
Introduction An abnormal serum potassium (SK) level is an important electrolyte
disturbance. However, its relation to clinical outcomes in real-world patients, particularly …
disturbance. However, its relation to clinical outcomes in real-world patients, particularly …
Optimizing fracture prevention: the fracture liaison service, an observational study
DA Eekman, SH Van Helden, AM Huisman… - Osteoporosis …, 2014 - Springer
The response rate to the invitation to the fracture liaison service and reasons for non-
response were evaluated in 2,207 fragility fracture patients. Fifty-one percent responded; …
response were evaluated in 2,207 fragility fracture patients. Fifty-one percent responded; …
Bisphosphonate use and the risk of undergoing total knee arthroplasty in osteoporotic patients with osteoarthritis: a nationwide cohort study in Taiwan
SH Fu, CY Wang, RS Yang, FLL Wu, FY Hsiao - JBJS, 2017 - journals.lww.com
Background: The use of bisphosphonates has been reported to have potential beneficial
effects on knee osteoarthritis, but existing studies have limitations. The purpose of this study …
effects on knee osteoarthritis, but existing studies have limitations. The purpose of this study …
[HTML][HTML] GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab
P Hadji, I Kyvernitakis, PH Kann, C Niedhart… - Osteoporosis …, 2016 - Springer
This retrospective database study assessed 2-year persistence with bisphosphonates or
denosumab in a large German cohort of women with a first-time prescription for osteoporosis …
denosumab in a large German cohort of women with a first-time prescription for osteoporosis …
Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States
LI Cheng, E Durden, B Limone, L Radbill… - Journal of managed …, 2015 - jmcp.org
BACKGROUND: Prior research has shown that rates of persistence and compliance with
osteoporosis therapies are associated with significantly fewer vertebral, nonvertebral, and …
osteoporosis therapies are associated with significantly fewer vertebral, nonvertebral, and …
[HTML][HTML] Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study
SL Silverman, E Siris, DL Kendler, D Belazi… - Osteoporosis …, 2015 - Springer
To determine persistence with subcutaneous denosumab every 6 months in women being
treated for osteoporosis, we conducted a single-arm prospective, observational study in the …
treated for osteoporosis, we conducted a single-arm prospective, observational study in the …
[HTML][HTML] Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal …
A Fahrleitner-Pammer, N Papaioannou, E Gielen… - Archives of …, 2017 - Springer
Persistence with osteoporosis therapy is vital for fracture prevention. This non-interventional
study of postmenopausal women receiving denosumab in Germany, Austria, Greece, and …
study of postmenopausal women receiving denosumab in Germany, Austria, Greece, and …